1 September 2024

Starpharma receives $4.7M R&D tax incentives

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditures, following the lodgement of the Company’s annual income tax return.

 

The R&D tax refund relates to eligible Australian R&D expenditure, and previously announced overseas findings relating to Starpharma’s VivaGel®, and DEP™ docetaxel clinical programs.

 

 Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:

 

 “The R&D tax incentive allows Starpharma to confidently advance development of its proprietary products including the clinical programs for VivaGel® and DEPTM docetaxel. In the case of DEP™ docetaxel, it supports the conduct of the clinical trial in Australia with the additional benefit that Australian patients will be the first in the world to have access to Starpharma’s improved version of the widely used cancer drug, docetaxel.”

 

Download ASX Announcement: Starpharma receives $4.7M R&D tax incentive ( pdf file, 335kb) 

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.